spacer
home > epc > spring 2017 > transforming software
PUBLICATIONS
European Pharmaceutical Contractor

Transforming Software

With the wide-scale adoption of clinical technologies, focus has slowly shifted from ‘how can we leverage new software and systems in our clinical trials?’ to ‘how can we best implement this software once we’ve chosen it?’ In a highly regulated industry, with patient safety and new treatment advances at stake, the priority has historically been compliance and risk management. Now that these systems are mature and reliable, identifying new ways to make them available in a more efficient and timely manner is important. Utilising iterative design is one way to address these needs.

The Triple Constraint

Anyone who has developed software or managed projects is familiar with the triangle concept – any movement of one factor impacts the equilibrium. For example, increasing the complexity of a clinical supply tool is sure to extend time to implement and development costs. Using an iterative approach helps manage these constraints as well as scope, and maintain quality while reducing time and cost.

Innovation to Date


Quality is of paramount importance with a clinical interactive response technology (IRT) system. When patients are being treated and new drugs developed, quality cannot be compromised. This quality profile must be maintained amid increasingly complex protocol designs, shorter timeline requirements and tighter budgets.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Steve Rawbone
spacer
spacer
spacer
Stephane Delegar
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI Worldwide: TE-ring remains firmly attached to the dropper bottle in line with FDA requirements

Düsseldorf/Frankfurt, October 24, 2017 – It is often only minor improvements that make a product ideal to use. The TE-ring fixed to the type A eye-dropper bottle in accordance with the new FDA regulations is one good example.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

14th World Advanced Therapies & Regenerative Medicine Congress 2018

16-18 May 2018, Business Design Centre, London, United Kingdom

In May 2018 the World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement